Electra Therapeutics raised $183 million in an oversubscribed Series C to support a global pivotal program for ELA026, its monoclonal antibody targeting SIRP receptors for secondary hemophagocytic lymphohistiocytosis (sHLH), and to advance additional inflammatory and hematologic indications. The company has dosed first patients in the pivotal portion of its Phase Ib‑II/III SURPASS study. ELA026 is designed to deplete pathogenic myeloid and lymphoid populations driving hyperinflammation; Electra also plans to push a second candidate, ELA822, into the clinic. CEO Kathy Dong emphasized that the financing positions the company to execute registrational trials and expand into oncology and I&I indications. The round — and backing by biotech investors — highlights continued venture support for niche, high‑impact immunology programs targeting cytokine storm syndromes and rare hyperinflammatory diseases.